4,901 trials
Healthy
Primary: AUCτ,ss (Fed Conditions) — 33.7; 32.3 ng·h/mL
Type 2 Diabetes
Primary: Area Under the Curve (AUC(0-t)) for Sitagliptin — 1570; 1590; 1520; 1600 hr*ng/mL
Leukemia
Primary: Average Total Body Clearance (Calculated From Rate and Concentration) — 129 L/hr/m^2
Dermatomyositis
Primary: Occurrence of at Least One Adverse Event — 1; 1; 5; 1 participants
Human Papilloma Virus · Cervical Cancer · Vulvar Cancer
Primary: Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase A — 1273.3; 2203.0; 4784.7; 1991.6 mMU/mL
HIV Infections
Primary: Ribavirin Maximum Plasma Concentration — 630.09; 496.71 ng/mL
Hypertension
Primary: 7-Day Physical Activity Recall (7-Day PAR) — 54.85; 44.89 minutes
Healthy
Primary: Cmax of Norethindrone — 4.3306; 4.2282 ng/mL
Bioequivalence
Primary: Cmax of Norethindrone — 10.94; 10.00 ng/mL
Diabetes Mellitus
Primary: Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) — 107.28; 111.72; 103.35 ng*hr/mL
Diabetes Mellitus
Primary: Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) — 99.45; 105.28 ng*hr/mL
Type 2 Diabetes Mellitus (T2DM)
Primary: Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6 — -83.9; 27.0 mg*hr/dL — p=<0.001
Contraception
Primary: Area Under the Curve (AUC) From Time 0 to 24 Weeks [AUC(0-24weeks)] for Plasma Folate and RBC (Red Blood Cell) Folate (Baseline Uncorrected) — 1030; 904; 24176; 21876…
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 3.087; 2.616 ng/mL
Osteoporosis
Primary: Part 1: Urinary Excretion of Alendronate — 133.6; 132.2 μg